Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries

Global pharma major Lupin Limited has signed a licensing and supply agreement with Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. The agreement covers 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America. Lupin will handle regulatory submissions, approvals, and commercialization and distribution, while Galenicum will oversee development, manufacturing, and supply. Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite, and is mainly prescribed for adults with Type 2 Diabetes and for long-term weight management in adults with obesity or overweight conditions.